ANI Pharmaceuticals, Inc. has raised its annual guidance for the second quarter in a row, as launch momentum remained strong for Cortrophin gel (repository corticotropin injection) 80 U/ml with a record number of new patient starts and new unique subscribers. The rest of the business also delivered strong results during the quarter, as ANI received four generic ANDA approvals and expanded its commercialization efforts into several new sales channels.
The company now expects net revenue of $425m-$445m, compared to a previous estimate of $385m-$410m, for the full year of...
